Index report of cutaneous angiosarcomas with strong positivity for tyrosinase mimicking melanoma with further evaluation of melanocytic markers in a large angiosarcoma series.
Identifieur interne : 000176 ( PubMed/Curation ); précédent : 000175; suivant : 000177Index report of cutaneous angiosarcomas with strong positivity for tyrosinase mimicking melanoma with further evaluation of melanocytic markers in a large angiosarcoma series.
Auteurs : Alicia Leon-Castillo [Espagne] ; John S A. Chrisinger [États-Unis] ; Gauri Panse [États-Unis] ; Rashmi T. Samdani [États-Unis] ; Davis R. Ingram [États-Unis] ; Vinod Ravi [États-Unis] ; Victor G. Prieto [États-Unis] ; Wei-Lien Wang [États-Unis] ; Alexander J. Lazar [États-Unis]Source :
- Journal of cutaneous pathology [ 1600-0560 ] ; 2017.
Abstract
Cutaneous angiosarcoma can be challenging to diagnose particularly when poorly vasoformative and studied on biopsies. We report a case of a cutaneous angiosarcoma with strong positivity for tyrosinase, the first to our knowledge, initially misdiagnosed as melanoma. We subsequently evaluated the reactivity of panmelanocytic cocktail (tyrosinase, HMB-45 and Melan-A), SOX10, tyrosinase and MITF in a large tissue microarray (TMA) of angiosarcoma. The TMA included 142 cases of angiosarcomas (29 cutaneous, 22 primary breast, 41 post-radiation breast, 15 visceral, 26 deep soft tissue and bone, 5 chronic lymphedema-associated and 4 angiosarcomas arising in other sarcomas). Immunohistochemical studies were performed with anti-panmelanocytic cocktail, anti-SOX10, anti-MITF and anti-tyrosinase antibodies. TMA staining results were scored on intensity and percentage of tumoral labeling. Aside from the index case, no cases (0 of 133) showed positivity for tyrosinase including 28 cutaneous angiosarcomas. One breast angiosarcoma (1 of 131) was positive for MITF. All cases were negative for SOX10 and panmelanocytic cocktail (0 of 132). Angiosarcomas can rarely be positive for tyrosinase and MITF. Pathologists should be cognizant of these rare exceptions to prevent confusion with melanoma. Additional immunohistochemical markers for vascular and melanocytic differentiation, thorough histological examination for vasoformative and in situ areas as well as clinical impression are helpful in these exceptionally problematic cases.
DOI: 10.1111/cup.12968
PubMed: 28556023
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000176
Links to Exploration step
pubmed:28556023Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Index report of cutaneous angiosarcomas with strong positivity for tyrosinase mimicking melanoma with further evaluation of melanocytic markers in a large angiosarcoma series.</title><author><name sortKey="Leon Castillo, Alicia" sort="Leon Castillo, Alicia" uniqKey="Leon Castillo A" first="Alicia" last="Leon-Castillo">Alicia Leon-Castillo</name><affiliation wicri:level="1"><nlm:affiliation>Pathology Service, Hospital Universitario Marques de Valdecilla, Santander, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Pathology Service, Hospital Universitario Marques de Valdecilla, Santander</wicri:regionArea></affiliation></author><author><name sortKey="Chrisinger, John S A" sort="Chrisinger, John S A" uniqKey="Chrisinger J" first="John S A" last="Chrisinger">John S A. Chrisinger</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Texas</region></placeName><wicri:cityArea>Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston</wicri:cityArea></affiliation></author><author><name sortKey="Panse, Gauri" sort="Panse, Gauri" uniqKey="Panse G" first="Gauri" last="Panse">Gauri Panse</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pathology, Yale University, New Haven, Connecticut.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Connecticut</region></placeName><wicri:cityArea>Department of Pathology, Yale University, New Haven</wicri:cityArea></affiliation></author><author><name sortKey="Samdani, Rashmi T" sort="Samdani, Rashmi T" uniqKey="Samdani R" first="Rashmi T" last="Samdani">Rashmi T. Samdani</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Texas</region></placeName><wicri:cityArea>Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston</wicri:cityArea></affiliation></author><author><name sortKey="Ingram, Davis R" sort="Ingram, Davis R" uniqKey="Ingram D" first="Davis R" last="Ingram">Davis R. Ingram</name><affiliation wicri:level="2"><nlm:affiliation>Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Texas</region></placeName><wicri:cityArea>Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston</wicri:cityArea></affiliation></author><author><name sortKey="Ravi, Vinod" sort="Ravi, Vinod" uniqKey="Ravi V" first="Vinod" last="Ravi">Vinod Ravi</name><affiliation wicri:level="2"><nlm:affiliation>Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Texas</region></placeName><wicri:cityArea>Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston</wicri:cityArea></affiliation></author><author><name sortKey="Prieto, Victor G" sort="Prieto, Victor G" uniqKey="Prieto V" first="Victor G" last="Prieto">Victor G. Prieto</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Texas</region></placeName><wicri:cityArea>Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston</wicri:cityArea></affiliation></author><author><name sortKey="Wang, Wei Lien" sort="Wang, Wei Lien" uniqKey="Wang W" first="Wei-Lien" last="Wang">Wei-Lien Wang</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Texas</region></placeName><wicri:cityArea>Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston</wicri:cityArea></affiliation></author><author><name sortKey="Lazar, Alexander J" sort="Lazar, Alexander J" uniqKey="Lazar A" first="Alexander J" last="Lazar">Alexander J. Lazar</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Texas</region></placeName><wicri:cityArea>Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston</wicri:cityArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28556023</idno><idno type="pmid">28556023</idno><idno type="doi">10.1111/cup.12968</idno><idno type="wicri:Area/PubMed/Corpus">000176</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000176</idno><idno type="wicri:Area/PubMed/Curation">000176</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000176</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Index report of cutaneous angiosarcomas with strong positivity for tyrosinase mimicking melanoma with further evaluation of melanocytic markers in a large angiosarcoma series.</title><author><name sortKey="Leon Castillo, Alicia" sort="Leon Castillo, Alicia" uniqKey="Leon Castillo A" first="Alicia" last="Leon-Castillo">Alicia Leon-Castillo</name><affiliation wicri:level="1"><nlm:affiliation>Pathology Service, Hospital Universitario Marques de Valdecilla, Santander, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Pathology Service, Hospital Universitario Marques de Valdecilla, Santander</wicri:regionArea></affiliation></author><author><name sortKey="Chrisinger, John S A" sort="Chrisinger, John S A" uniqKey="Chrisinger J" first="John S A" last="Chrisinger">John S A. Chrisinger</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Texas</region></placeName><wicri:cityArea>Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston</wicri:cityArea></affiliation></author><author><name sortKey="Panse, Gauri" sort="Panse, Gauri" uniqKey="Panse G" first="Gauri" last="Panse">Gauri Panse</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pathology, Yale University, New Haven, Connecticut.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Connecticut</region></placeName><wicri:cityArea>Department of Pathology, Yale University, New Haven</wicri:cityArea></affiliation></author><author><name sortKey="Samdani, Rashmi T" sort="Samdani, Rashmi T" uniqKey="Samdani R" first="Rashmi T" last="Samdani">Rashmi T. Samdani</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Texas</region></placeName><wicri:cityArea>Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston</wicri:cityArea></affiliation></author><author><name sortKey="Ingram, Davis R" sort="Ingram, Davis R" uniqKey="Ingram D" first="Davis R" last="Ingram">Davis R. Ingram</name><affiliation wicri:level="2"><nlm:affiliation>Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Texas</region></placeName><wicri:cityArea>Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston</wicri:cityArea></affiliation></author><author><name sortKey="Ravi, Vinod" sort="Ravi, Vinod" uniqKey="Ravi V" first="Vinod" last="Ravi">Vinod Ravi</name><affiliation wicri:level="2"><nlm:affiliation>Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Texas</region></placeName><wicri:cityArea>Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston</wicri:cityArea></affiliation></author><author><name sortKey="Prieto, Victor G" sort="Prieto, Victor G" uniqKey="Prieto V" first="Victor G" last="Prieto">Victor G. Prieto</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Texas</region></placeName><wicri:cityArea>Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston</wicri:cityArea></affiliation></author><author><name sortKey="Wang, Wei Lien" sort="Wang, Wei Lien" uniqKey="Wang W" first="Wei-Lien" last="Wang">Wei-Lien Wang</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Texas</region></placeName><wicri:cityArea>Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston</wicri:cityArea></affiliation></author><author><name sortKey="Lazar, Alexander J" sort="Lazar, Alexander J" uniqKey="Lazar A" first="Alexander J" last="Lazar">Alexander J. Lazar</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Texas</region></placeName><wicri:cityArea>Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston</wicri:cityArea></affiliation></author></analytic><series><title level="j">Journal of cutaneous pathology</title><idno type="eISSN">1600-0560</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Cutaneous angiosarcoma can be challenging to diagnose particularly when poorly vasoformative and studied on biopsies. We report a case of a cutaneous angiosarcoma with strong positivity for tyrosinase, the first to our knowledge, initially misdiagnosed as melanoma. We subsequently evaluated the reactivity of panmelanocytic cocktail (tyrosinase, HMB-45 and Melan-A), SOX10, tyrosinase and MITF in a large tissue microarray (TMA) of angiosarcoma. The TMA included 142 cases of angiosarcomas (29 cutaneous, 22 primary breast, 41 post-radiation breast, 15 visceral, 26 deep soft tissue and bone, 5 chronic lymphedema-associated and 4 angiosarcomas arising in other sarcomas). Immunohistochemical studies were performed with anti-panmelanocytic cocktail, anti-SOX10, anti-MITF and anti-tyrosinase antibodies. TMA staining results were scored on intensity and percentage of tumoral labeling. Aside from the index case, no cases (0 of 133) showed positivity for tyrosinase including 28 cutaneous angiosarcomas. One breast angiosarcoma (1 of 131) was positive for MITF. All cases were negative for SOX10 and panmelanocytic cocktail (0 of 132). Angiosarcomas can rarely be positive for tyrosinase and MITF. Pathologists should be cognizant of these rare exceptions to prevent confusion with melanoma. Additional immunohistochemical markers for vascular and melanocytic differentiation, thorough histological examination for vasoformative and in situ areas as well as clinical impression are helpful in these exceptionally problematic cases.</div></front></TEI><pubmed><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">28556023</PMID><DateCreated><Year>2017</Year><Month>05</Month><Day>30</Day></DateCreated><DateRevised><Year>2017</Year><Month>07</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1600-0560</ISSN><JournalIssue CitedMedium="Internet"><Volume>44</Volume><Issue>8</Issue><PubDate><Year>2017</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Journal of cutaneous pathology</Title><ISOAbbreviation>J. Cutan. Pathol.</ISOAbbreviation></Journal><ArticleTitle>Index report of cutaneous angiosarcomas with strong positivity for tyrosinase mimicking melanoma with further evaluation of melanocytic markers in a large angiosarcoma series.</ArticleTitle><Pagination><MedlinePgn>692-697</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/cup.12968</ELocationID><Abstract><AbstractText>Cutaneous angiosarcoma can be challenging to diagnose particularly when poorly vasoformative and studied on biopsies. We report a case of a cutaneous angiosarcoma with strong positivity for tyrosinase, the first to our knowledge, initially misdiagnosed as melanoma. We subsequently evaluated the reactivity of panmelanocytic cocktail (tyrosinase, HMB-45 and Melan-A), SOX10, tyrosinase and MITF in a large tissue microarray (TMA) of angiosarcoma. The TMA included 142 cases of angiosarcomas (29 cutaneous, 22 primary breast, 41 post-radiation breast, 15 visceral, 26 deep soft tissue and bone, 5 chronic lymphedema-associated and 4 angiosarcomas arising in other sarcomas). Immunohistochemical studies were performed with anti-panmelanocytic cocktail, anti-SOX10, anti-MITF and anti-tyrosinase antibodies. TMA staining results were scored on intensity and percentage of tumoral labeling. Aside from the index case, no cases (0 of 133) showed positivity for tyrosinase including 28 cutaneous angiosarcomas. One breast angiosarcoma (1 of 131) was positive for MITF. All cases were negative for SOX10 and panmelanocytic cocktail (0 of 132). Angiosarcomas can rarely be positive for tyrosinase and MITF. Pathologists should be cognizant of these rare exceptions to prevent confusion with melanoma. Additional immunohistochemical markers for vascular and melanocytic differentiation, thorough histological examination for vasoformative and in situ areas as well as clinical impression are helpful in these exceptionally problematic cases.</AbstractText><CopyrightInformation>© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Leon-Castillo</LastName><ForeName>Alicia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Pathology Service, Hospital Universitario Marques de Valdecilla, Santander, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chrisinger</LastName><ForeName>John S A</ForeName><Initials>JSA</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-7138-0923</Identifier><AffiliationInfo><Affiliation>Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Panse</LastName><ForeName>Gauri</ForeName><Initials>G</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-5762-3490</Identifier><AffiliationInfo><Affiliation>Department of Pathology, Yale University, New Haven, Connecticut.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Samdani</LastName><ForeName>Rashmi T</ForeName><Initials>RT</Initials><AffiliationInfo><Affiliation>Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ingram</LastName><ForeName>Davis R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ravi</LastName><ForeName>Vinod</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prieto</LastName><ForeName>Victor G</ForeName><Initials>VG</Initials><AffiliationInfo><Affiliation>Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Wei-Lien</ForeName><Initials>WL</Initials><AffiliationInfo><Affiliation>Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lazar</LastName><ForeName>Alexander J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>06</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Cutan Pathol</MedlineTA><NlmUniqueID>0425124</NlmUniqueID><ISSNLinking>0303-6987</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">MiTF</Keyword><Keyword MajorTopicYN="N">SOX10</Keyword><Keyword MajorTopicYN="N">angiosarcoma</Keyword><Keyword MajorTopicYN="N">melanoma</Keyword><Keyword MajorTopicYN="N">panmelanocytic</Keyword><Keyword MajorTopicYN="N">tyrosinase</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>02</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>05</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>05</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>5</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>5</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>5</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28556023</ArticleId><ArticleId IdType="doi">10.1111/cup.12968</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000176 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000176 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:28556023
|texte= Index report of cutaneous angiosarcomas with strong positivity for tyrosinase mimicking melanoma with further evaluation of melanocytic markers in a large angiosarcoma series.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:28556023" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |